Online inquiry

IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10046MR)

This product GTTS-WQ10046MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN1 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10046MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7424MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ7981MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ3614MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ15575MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ11453MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ9517MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ4354MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ13897MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW